Trial intelligence / Profile preview

Rucaparib + Bevacizumab in Recurrent Cervical or Endometrial Cancer

NCT03476798Phase 2

Key facts

Status: Completed
Start: Jun 2018
Primary completion: May 2020
Countries: 1
Sponsor: University of Oklahoma
Modality: Small Molecules

Drugs: rucaparib
Conditions: Cervical Cancer (CC)endometrial cancer (EC)

Overview

Phase 2, open-label, single-arm trial of rucaparib in Cervical Cancer (CC) and endometrial cancer (EC), sponsored by University of Oklahoma. Primary endpoint: Proportion of Patients Who Are Progression-free at 6 Months. Started Jun 2018; status: completed.

Design

1 arm

Study design: Non-randomizedOpen-label

Bevacizumab + Rucaparib
Combination therapy with Rucaparib and Bevacizumab

Endpoints

Primary

Proportion of Patients Who Are Progression-free at 6 Months6 months

Secondary

Proportion of Patients Who Had Objective Tumor Responseup to 2 years
Number of Patients Who Experience Toxicityup to 2 years
Median Overall Survivalup to 2 years
Median Progression-free Survival Timeup to 2 years

Beyond the preview

Go deeper on NCT03476798.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT03476798.